Close Menu

Twist Bioscience

The index — which outperformed the Dow Jones, the Nasdaq, and the Biotechnology Index this month — gained more than 8 percent.

Twist continues to invest in NGS while growing its core synthetic biology business, and has filed a countercomplaint in its ongoing litigation with Agilent.

The firm recognized revenues in fiscal Q1 2019 of $11.5 million, driven by rapid growth in its NGS products as well as its synthetic biology business.

Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.

Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.

Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.

Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.

Cowen gave the company a rating of Outperform while JP Morgan assigned its shares a Neutral rating.

The firm hasn't yet specified how many shares it is offering or at what price but noted that its stock would trade under the Nasdaq symbol TWST.

Pages

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.